Biocon takes Advaxis into emerging markets through ADXS-HPV pact
This article was originally published in Scrip
Executive Summary
Biocon has entered into an exclusive licensing pact for the co-development and commercialization of Advaxis' lead cancer immunotherapy candidate for human papillomavirus (HPV)-associated cervical cancer, ADXS-HPV, in India and certain emerging markets.